Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?

Articles in the same Issue

1. Frontmatter
2. Editorials
3. Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
4. From Dr. Google to CE-marked medical devices: need for ethical and legal safeguards
5. Minireview
6. Antioxidant therapy for hepatic diseases: a double-edged sword
7. Reviews
8. Effect of cannabinoids in mild-to-moderate cases of Crohn’s disease as compared to placebo: a systematic review and meta-analysis of randomised controlled trials
9. Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer’s disease
10. Alzheimer’s disease and clinical trials
11. Original Articles
12. Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat
13. Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?
14. Gasotransmitters do not prevent changes in transepithelial ion transport induced by hypoxia followed by reoxygenation
15. High-intensity combination exercise has the highest effect on increasing serum irisin and interleukin 6 levels in women with obesity
16. Impact of heat stress on thermal balance, hydration and cortical response among outdoor workers in hot environment – an exploratory report from North East India
17. Maternal separation influences hepatic drug-metabolizing CYP450 gene expression without pathological changes in adult mice
18. Case Report
19. Preoperative CT diagnosis of perforated Meckel’s diverticulitis in a young patient: a case report